Comparison of Finasteride (Proscar) and Serenoa Repens (Permixon) in the Inhibition of 5-Alpha Reductase in Healthy Male Volunteers

    January 1994 in “ European Urology ”
    Georges Strauch, P Perles, Gerard Vergult … Marie-Pierre Malice
    Studysummary This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on karger.com →
    Discuss this study in the Community →

    Related research 3

    1. A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia Drug safety · 1998
    2. MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen The Journal of Clinical Endocrinology & Metabolism · 1997
    3. Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Serum Gonadotropins in Normal Men The Journal of Clinical Endocrinology and Metabolism · 1992